Zacks: Analysts Anticipate IDEAYA Biosciences (NASDAQ:IDYA) Will Announce Earnings of -$0.73 Per Share

Wall Street analysts expect IDEAYA Biosciences (NASDAQ:IDYA) to post earnings per share (EPS) of ($0.73) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for IDEAYA Biosciences’ earnings. The lowest EPS estimate is ($0.77) and the highest is ($0.69). The company is scheduled to announce its next quarterly earnings results on Monday, November 11th.

According to Zacks, analysts expect that IDEAYA Biosciences will report full-year earnings of ($2.91) per share for the current fiscal year, with EPS estimates ranging from ($2.98) to ($2.83). For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.43) per share, with EPS estimates ranging from ($3.72) to ($3.13). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for IDEAYA Biosciences.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Monday, August 12th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.66).

Several analysts have recently issued reports on the stock. Citigroup assumed coverage on shares of IDEAYA Biosciences in a research note on Monday, June 17th. They issued a “buy” rating and a $20.00 target price for the company. Jefferies Financial Group assumed coverage on shares of IDEAYA Biosciences in a research note on Monday, June 17th. They issued a “buy” rating and a $14.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of IDEAYA Biosciences in a research note on Monday, June 17th. They issued a “neutral” rating and a $15.00 target price for the company.

Shares of NASDAQ IDYA traded down $0.27 during trading on Friday, hitting $6.75. The stock had a trading volume of 20 shares, compared to its average volume of 13,744. IDEAYA Biosciences has a 12 month low of $6.55 and a 12 month high of $16.90. The company’s fifty day moving average price is $7.81.

In related news, major shareholder Alexandria Venture Investments purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were bought at an average cost of $10.00 per share, with a total value of $500,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Several large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. purchased a new position in shares of IDEAYA Biosciences in the 2nd quarter worth about $1,948,000. Victory Capital Management Inc. purchased a new position in shares of IDEAYA Biosciences in the 2nd quarter worth about $1,453,000. Monashee Investment Management LLC purchased a new position in shares of IDEAYA Biosciences in the 2nd quarter worth about $354,000. Vanguard Group Inc. purchased a new stake in IDEAYA Biosciences during the second quarter valued at about $349,000. Finally, Laurion Capital Management LP purchased a new stake in IDEAYA Biosciences during the second quarter valued at about $199,000.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

See Also: What are the advantages to having securities held in street name?

Get a free copy of the Zacks research report on IDEAYA Biosciences (IDYA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.